S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
pixel
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
pixel
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
pixel
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
pixel
Log in
NASDAQ:APLS

Apellis Pharmaceuticals Stock Forecast, Price & News

$42.64
-2.25 (-5.01 %)
(As of 01/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$41.89
Now: $42.64
$44.56
50-Day Range
$44.89
MA: $52.98
$57.39
52-Week Range
$16.85
Now: $42.64
$58.47
Volume819,012 shs
Average Volume699,163 shs
Market Capitalization$3.23 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.47
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin disease, C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration. Apellis Pharmaceuticals, Inc. has a strategic collaboration with Swedish Orphan Biovitrum AB (publ) for the advancement of pegcetacoplan, a C3 therapy for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. The company was founded in 2009 and is based in Waltham, Massachusetts.
Apellis Pharmaceuticals logo

MarketRank

Overall MarketRank

1.75 out of 5 stars

Medical Sector

164th out of 1,926 stocks

Pharmaceutical Preparations Industry

81st out of 772 stocks

Analyst Opinion: 4.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APLS
CUSIPN/A
Phone617-977-5700
Employees350
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.46 per share

Profitability

Net Income$-304,710,000.00

Miscellaneous

Market Cap$3.23 billion
Next Earnings Date2/25/2021 (Estimated)
OptionableNot Optionable
$42.64
-2.25 (-5.01 %)
(As of 01/27/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive APLS News and Ratings via Email

Sign-up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions

How has Apellis Pharmaceuticals' stock been impacted by COVID-19?

Apellis Pharmaceuticals' stock was trading at $27.23 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, APLS shares have increased by 56.6% and is now trading at $42.64.
View which stocks have been most impacted by COVID-19
.

Is Apellis Pharmaceuticals a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 4 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Apellis Pharmaceuticals stock.
View analyst ratings for Apellis Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Apellis Pharmaceuticals?

Wall Street analysts have given Apellis Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Apellis Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO?

6 employees have rated Apellis Pharmaceuticals CEO Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among Apellis Pharmaceuticals' employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Apellis Pharmaceuticals' next earnings date?

Apellis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Apellis Pharmaceuticals
.

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) released its earnings results on Saturday, November, 7th. The company reported ($1.79) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.58) by $0.21. The firm earned $0.65 million during the quarter.
View Apellis Pharmaceuticals' earnings history
.

What price target have analysts set for APLS?

15 equities research analysts have issued 1-year target prices for Apellis Pharmaceuticals' stock. Their forecasts range from $29.00 to $875.00. On average, they expect Apellis Pharmaceuticals' share price to reach $117.57 in the next twelve months. This suggests a possible upside of 175.7% from the stock's current price.
View analysts' price targets for Apellis Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of Apellis Pharmaceuticals' key competitors?

What other stocks do shareholders of Apellis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

Who are Apellis Pharmaceuticals' key executives?

Apellis Pharmaceuticals' management team includes the following people:
  • Dr. Cedric Francois, Co-Founder, Pres, CEO & Director (Age 49, Pay $987.91k)
  • Dr. Pascal Deschatelets, Co-Founder & Chief Scientific Officer (Age 51, Pay $712.58k)
  • Mr. Alec Machiels J.D., MBA, Co-Founder & Independent Director (Age 48, Pay $61.75k)
  • Mr. Timothy E. Sullivan, Chief Financial Officer (Age 50, Pay $610.65k)
  • Dr. Federico Grossi M.D., Ph.D., Co-Founder & Chief Medical Officer (Age 47)
  • Ms. Nur Nicholson, Chief Technical Operations Officer
  • Mr. David O. Watson, Gen. Counsel (Age 48)
  • Ms. Karen Lewis, Chief People Officer
  • Dr. Lukas Scheibler M.D., Ph.D., Chief Innovation Officer (Age 50)
  • Mr. Adam J. Townsend, Chief Commercial Officer (Age 44)

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an IPO on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO.

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Who are Apellis Pharmaceuticals' major shareholders?

Apellis Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.73%), Rhenman & Partners Asset Management AB (0.36%), DNB Asset Management AS (0.05%), Strs Ohio (0.00%), Nisa Investment Advisors LLC (0.00%) and Pacer Advisors Inc. (0.00%). Company insiders that own Apellis Pharmaceuticals stock include A Sinclair Dunlop, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, Morningside Venture Investment, Nicole D Perry, Pascal Deschatelets, Timothy Eugene Sullivan and Victoria L Brown.
View institutional ownership trends for Apellis Pharmaceuticals
.

Which institutional investors are selling Apellis Pharmaceuticals stock?

APLS stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., and Pacer Advisors Inc.. Company insiders that have sold Apellis Pharmaceuticals company stock in the last year include A Sinclair Dunlop, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, Nicole D Perry, and Victoria L Brown.
View insider buying and selling activity for Apellis Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Apellis Pharmaceuticals stock?

APLS stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, DNB Asset Management AS, Strs Ohio, and Nisa Investment Advisors LLC. Company insiders that have bought Apellis Pharmaceuticals stock in the last two years include Morningside Venture Investment, and Timothy Eugene Sullivan.
View insider buying and selling activity for Apellis Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Apellis Pharmaceuticals' stock price today?

One share of APLS stock can currently be purchased for approximately $42.64.

How big of a company is Apellis Pharmaceuticals?

Apellis Pharmaceuticals has a market capitalization of $3.23 billion. The company earns $-304,710,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis. Apellis Pharmaceuticals employs 350 workers across the globe.

What is Apellis Pharmaceuticals' official website?

The official website for Apellis Pharmaceuticals is www.apellis.com.

How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The company can be reached via phone at 617-977-5700 or via email at [email protected]

This page was last updated on 1/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.